Nuvectis Pharma financials
$20.53−1.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M |
| Net income | -$28.9M | -$19.0M | -$22.3M | -$19.1M |
| Net margin | — | — | — | — |
| Diluted EPS | $-1.32 | $-1.11 | $-1.43 | $-1.51 |
| EBITDA | -$27.6M | -$19.8M | -$22.9M | -$19.2M |
| Operating cash flow | -$16.0M | -$12.2M | -$16.0M | -$13.6M |
| Free cash flow | -$16.0M | -$12.2M | -$16.0M | -$13.6M |
| Diluted shares | 21.8M | 17.1M | 15.6M | 12.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $31.6M | $18.5M | $19.1M | $20.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M |
| Shareholders' equity | $18.4M | $9.7M | $12.2M | $14.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology